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Regulation of the parathyroid hormone gene by vitamin D, late the PTH gene and these will be considered in the
calcium, and phosphate. Secondary hyperparathyroidism is a present review.
frequent complication of chronic renal failure resulting in se-
vere bone disease. Secondary hyperparathyroidism is com-
posed of increased in parathyroid hormone (PTH) synthesis THE PTH GENE
and secretion due to an increase in PTH gene expression and
The parathyroid cell is committed to the synthesis ofparathyroid cell proliferation. PTH gene expression is regu-
lated by calcium, phosphate and 1,25-dihydroxy vitamin D PTH, implying that there are specific trans- and cis-fac-
(1,25(OH)2D). 1,25(OH)2D3 injected to rats leads to a dramatic tors acting on the PTH gene that are specific to the cell
decrease in PTH gene transcription without any increase in and gene. The gene itself is expressed once in the human
serum calcium. Hypocalcemia leads to a large increase in PTH
genome and is a relatively simple gene. It has been clonedmRNA levels which is post-transcriptional. Hypophosphate-
in a number of species and in all species it consists ofmia leads to a marked decrease in PTH gene expression that
is also post-transcriptional. The mechanisms of the post-tran- three exons and two introns. These exons code for the
scriptional effects of calcium and phosphate on the PTH gene 59-untranslated region and the presequence of the gene,
have shown to be due to changes in protein–RNA interactions the pro-sequence and for the translated hormone and
at the PTH mRNA 39-UTR. Hypocalcemia leads to increased the 39-untranslated region, respectively. The PTH genebinding of parathyroid cytosolic proteins to the PTH mRNA
is present in humans on the short arm of chromosome 11.39-UTR and hypophosphatemia to decreased binding of these
The PTH promoter contains a canonical cAMP-proteins to the PTH mRNA 39-UTR. The binding of the para-
thyroid proteins stabilizes the PTH RNA in an in vitro degrada- responsive element 59-TGACGTCA-39 at position 281
tion assay. In rats with experimental uremia due to 5/6 nephrec- with a single residue deviation [1]. This element was
tomy, there is an increase in PTH mRNA levels due to a fused to a reporter gene (CAT) and then transfected into
decrease in degradation of the PTH RNA as determined by
different cell lines. Pharmacological agents that increasethis assay. The characterization of the parathyroid cytosolic
cyclic adenosine 39,59 monophosphate (cAMP) lead toproteins that interact with the PTH mRNA 39-UTR may lead
to a clearer understanding of how changes in serum calcium an increased expression of the CAT gene, suggesting a
and phosphate result in secondary hyperparathyroidism. functional role for the cAMP-responsive element (CRE).
The role of this possible CRE in the context of the
PTH gene in the parathyroid remains to be established.
The expression of the parathyroid hormone (PTH) However, pharmacological agents that stimulate and in-
gene is regulated by a number of factors, the most impor- hibit PTH secretion and PTH mRNA levels in vitro in
tant in physiology being the serum calcium. However, primary cultures of parathyroid cell certainly regulate
the PTH gene is also powerfully regulated by other fac- these activities by their actions on the protein kinase A
tors; those of most relevance to the nephrologist are and C pathways. For example, dopamine, which stimulates
vitamin D and serum phosphate. There has been recent cAMP synthesis, increases PTH secretion [2]. Stimulation
progress in the understanding of how these factors regu- of the calcium-sensing receptor by hypercalcemia stimu-
lates the protein kinase C pathway with an increase in
inositol triphosphate and mobilization of intracellular cal-
1 C.Y. was on sabbatical leave from Erciyes University Medical School, cium [3]. There is a subsequent decrease in PTH secretion.Kayseri, Turkey.
Demay et al [4] identified DNA sequences in the hu-
Key words: calcium, parathyroid hormone, phosphate, vitamin D. man PTH gene that bind the 1,25(OH)2D3 receptor. Nu-
clear extracts containing the 1,25(OH)2D3 receptor were 1999 by the International Society of Nephrology
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examined for binding to sequences in the 59-flanking mRNA levels in the parathyroid (PT) glands in contrast
to the decrease in PTH mRNA levels. The localizationregion of the human PTH gene. A 25-bp oligonucleotide
containing the sequences from 2125 to 2101 from the of the VDR mRNA to the PTs was demonstrated by in
situ hybridization studies of the thyro-parathyroid andstart of exon 1 bound nuclear proteins, which were recog-
nized by monoclonal antibodies against the 1,25- duodenum. VDR mRNA was localized to the PTs in the
same concentration as in the duodenum, the classic target(OH)2D3 receptor. The sequences in this region con-
tained a single copy of a motif (AGGTTCA) that is organ for 1,25(OH)2D3.
In chronic renal failure there may be other factorshomologous to the motifs repeated in the upregu-
latory 1,25(OH)2D3-response element of osteocalcin. that result in resistance to the action of 1,25(OH)2D3
[15]. A uremic plasma ultrafiltrate resulted in a decreaseWhen placed upstream to a heterologous viral pro-
moter, the sequences contained in this 25-bp oligo- in the binding sites for the VDR to the osteocalcin
VDRE. Therefore, uremic toxin(s) may inhibit VDR-nucleotide mediated transcriptional repression in re-
sponse to 1,25(OH)2-D3 in GH4C1 cells but not in ROS VDRE binding and contribute to the 1,25(OH)2D3 resis-
tance of renal failure.17/2.8 cells. Therefore, this downregulatory element
differs from upregulatory elements both in sequence
Calreticulin and the action of 1,25(OH)2D3 on thecomposition and in the requirement for particular cellu-
PTH genelar factors other than the 1,25(OH)2D3 receptor (VDR)
for repressing PTH transcription [4]. Farrow et al [5, 6] Calreticulin has been shown to prevent vitamin D’s
binding and action on the osteocalcin gene in vitro [16].have identified DNA sequences upstream of the bovine
PTH gene that bind the 1,25(OH)2D3 receptor. Liu et al Sela-Brown et al showed that calreticulin might inhibit
vitamin D’s action on the PTH gene [17]. Both rat and[7] have identified such sequences in the chicken PTH
gene and demonstrated their functionality after trans- chicken VDRE sequences of the PTH gene were incu-
bated with recombinant VDR and retinoic acid receptorfection into the opossum kidney OK cell line.
(RXR) proteins in a gel retardation assay and showed
a clear retarded band. Purified calreticulin inhibited
REGULATION OF PTH GENE EXPRESSION
binding of the VDR-RXR complex to the VDREs in
1,25-dihydroxyvitamin D gel retardation assays. This inhibition was due to direct
protein–protein interactions between the VDR and cal-1,25(OH)2D3 potently decreases the transcription of
the PTH gene. This action was first demonstrated in vitro reticulin. Opossum kidney (OK) cells were transiently
cotransfected with calreticulin expression vectors (sensein bovine parathyroid cells in primary culture, where
1,25(OH)2D3 led to a marked decrease in PTH mRNA and antisense) and either rat or chicken PTH gene pro-
moter-CAT constructs. The cells were then assayed forlevels [8, 9] and a consequent decrease in PTH secretion
[10]. The physiological relevance of these findings was 1,25(OH)2D3 induced CAT gene expression. 1,25(OH)2-
D3 decreased PTH promoter-CAT transcription. Cotrans-established by in vivo studies in rats [11]. Rats injected
with amounts of 1,25(OH)2D3, which did not increase fection with sense calreticulin, which increases calreti-
culin protein levels, completely inhibited the effect ofserum calcium had marked decreases in PTH mRNA
levels, reaching ,4% of control at 48 hr. This effect was 1,25(OH)2D3 on the PTH promoters of both rat and
chicken. Cotransfection with the antisense calreticulinshown to be transcriptional both in in vivo studies in
rats [11] and in in vitro studies with primary cultures of construct did not interfere with vitamin D’s effect on
PTH gene transcription. Sense calreticulin expressionbovine parathyroid cells [12]. When 684 base pairs of
the 59-flanking region of the human PTH gene was linked had no effect on basal CAT mRNA levels. In order
to determine a physiological role for calreticulin in theto a reporter gene and transfected into a rat pituitary
cell line (GH4C1), gene expression was lowered by regulation of the PTH gene, the levels of calreticulin
protein were determined in the nuclear fraction of rat1,25(OH)2D3 [13]. These studies suggest that 1,25-
(OH)2D3 decreases PTH transcription by acting on the parathyroids. The rats were fed either a control diet or
a low calcium diet, which leads to increased PTH mRNA59-flanking region of the PTH gene, probably at least
partly through interactions with the vitamin D binding levels despite high serum 1,25(OH)2D3 levels that would
be expected to inhibit PTH gene transcription [17]. Itsequence noted above.
A further level at which 1,25(OH)2D3 might regulate was postulated that high calreticulin levels in the nuclear
fraction would prevent the effect of 1,25(OH)2D3 on thethe PTH gene would be at the level of the 1,25(OH)2D3
receptor. Naveh-Many et al [14] injected 1,25(OH)2D3 to PTH gene. In fact, the hypocalcemic rats had increased
levels of calreticulin protein, as measured by Westernrats and measured the levels of the 1,25(OH)2D3 receptor
mRNA (VDR mRNA) and PTH mRNA in the para- blots, in their parathyroid nuclear fraction. This may
help explain why hypocalcemia leads to increased PTHthyro-thyroid tissue. They showed that 1,25(OH)2D3 in
physiologically relevant doses led to an increase in VDR gene expression despite high serum 1,25(OH)2D3 levels,
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and may also be relevant to the refractoriness of the
secondary hyperparathyroidism of many chronic renal
failure patients to 1,25(OH)2D3 treatment. These studies
therefore indicate a role for calreticulin in regulating the
effect of vitamin D on the PTH gene, and suggest a
physiological relevance to these studies [17].
Calcium
A remarkable characteristic of the PT is its sensitivity
to small changes in serum calcium, that is recognized by
a 7-transmembrane receptor with a large extracellular
(EC) amino-terminal region, the calcium-sensing recep-
tor (CaSR) [3, 18]. Small changes in extracellular calcium
lead to large changes in PTH secretion, with a sigmoidal
type response, which may be less sensitive in CRF. There
is downregulation of the CaSR protein in the PTs in end
stage renal disease [19]. A decrease in EC calcium leads
not only to an increase in PTH secretion but also to
increases in PTH mRNA levels and PT cell proliferation.
Hypocalcemia increases PTH secretion in the short term,
PTH mRNA levels in hours and days and PT cell number
after a more prolonged stimulus [20]. In vivo, small de-
creases in serum calcium lead to large increases in PTH
mRNA levels [21, 22]. However, large increases in serum
calcium do not decrease PTH mRNA levels [23].
MECHANISMS OF REGULATION OF PTH
mRNA BY CALCIUM
The mechanism whereby calcium regulates PTH gene
expression is particularly interesting. It is not known how
changes in extracellular calcium regulate PTH mRNA
levels. There is no PT cell line, so we have performed
in vivo studies on the effect of hypocalcemia to increase
PTH gene expression. The effect is post-transcriptional
in vivo and involves protein–RNA interactions at the 39-
untranslated region of the PTH mRNA [24]. A similar
mechanism is involved by the effect of phosphate on Fig. 1. In vitro degradation of PTH mRNA by parathyroid cytosolic
proteins. (A) Time response curves of intact full-length PTH mRNAPTH gene expression, so the mechanisms involved will
after incubation with parathyroid cytosolic proteins. Each point repre-be discussed after the independent effect of phosphate sents the mean 6 SE of 3–4 different experiments, apart from -Ca at
on the PT is considered. 240 and 300 min which is the mean of 2 experiments. At some points
the SE is less than the size of the graphic symbols. The PTH transcript
was degraded very rapidly by proteins from -P rats, and remained intactPhosphate
for a longer time period with proteins from -Ca rats. (B) Mapping a
A specific parathyroid cell sodium-phosphate cotrans- region in the PTH 39-UTR that mediates degradation by proteins from
-P rats. PTH mRNA probes used were: intact PTH mRNA (probe A),porter. Tatsumi et al have recently cloned a specific Na-
without the 39-UTR (probe C), and without the 39-terminal 60 nt ofphosphate cotransporter in the parathyroid [25, 26]. A the 39-UTR (probe B). (Reproduced with permission of The American
complementary DNA encoding a Na1-Pi cotransporter, Society for Biochemistry & Molecular Biology [24]).
termed rat PiT-1, was isolated from rat parathyroid. The
2890-bp complementary DNA encodes a protein of 681
amino acids that showed .90% sequence identities with
the type III Na1-Pi cotransporters, mouse and human bone, and small intestine. The abundance of PiT-1
PiT-1. Expression of rat PiT-1 in Xenopus oocytes re- mRNA in the parathyroid was much greater in rats fed
a low-Pi diet than in those fed a high-Pi diet. Therfore,vealed that it possessed Na1-dependent Pi cotransport
activity. PiT-1 messenger RNA (mRNA) is widely dis- the rat PiT-1 may contribute to the effects of Pi on
parathyroid function.tributed in rat tissues and was most abundant in brain,
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Fig. 2. Model of PTH mRNA including the
59-UTR, the coding region and the 39-UTR,
and the parathyroid cytosolic proteins that in-
teract with the 39UTR. The parathyroid pro-
teins contain both protective factors, measured
by UV cross-linking, and degrading factors
(endonucleases), measured by an in vitro deg-
radation assay. In normal rats, the basal levels
of PTH mRNA is determined by balance be-
tween the protective and degrading factors in
the cytoplasm. In hypocalcemia, there is an
increase in PTH mRNA associated with an
increase in the binding of protective factors
which leads to a more stable transcript. In
hypophosphatemia, there is a decrease in pro-
tective factors, which leads to a less stable
transcript and a decrease in PTH mRNA levels.
In rats with chronic renal failure due to 5/6
nephrectomy, there is no change in the protec-
tive factors together with a decrease in endo-
nuclease activity, resulting in increased PTH
mRNA levels. (Reproduced with permission
of the American Society of Nephrology [34]).
Phosphate regulates the parathyroid independently of hypophosphatemia with a large decrease in PTH mRNA
levels. In both instances the effect was post-transcrip-calcium and 1,25(OH)2D3. The contribution of hyper-
phosphatemia to the pathogenesis of the secondary hy- tional, as shown by nuclear transcript run on experi-
ments. PT cytosolic proteins were found to bind in vitroperparathyroidism of chronic renal failure has been doc-
umented for many years [27] but it was never possible transcribed PTH mRNA with three bands at about 50,
60 and 110 kDa [24]. What was particularly interestingto separate the effect of hyperphosphatemia from the
secondary decreases in serum calcium and 1,25(OH)2D3 that this binding was increased with parathyroid proteins
from hypocalcemic rats where PTH mRNA levels are[28]. This was first established by the work of Kilav et
al who succeeded in demonstrating that the effect of increased, and decreased with PT proteins from hypo-
phosphatemic rats, where PTH mRNA levels are de-serum phosphate on PTH gene expression and serum
PTH levels was independent of any changes in serum creased. There was protein binding to PTH mRNA with
proteins from many tissues but only with PT proteinscalcium or 1,25(OH)2D3 [29]. Second generation vitamin
D deficient weanling rats were fed a diet deficient in was this binding regulated by calcium and phosphate.
Intriguingly, the binding was dependent upon the termi-vitamin D and with a low calcium and a low phosphate
content. After one night of this diet, the serum phosphate nal 60 nt of the PTH transcript being present.
had markedly decreased with no changes in serum cal-
PTH mRNA degradation in vitro by PTcium or 1,25(OH)2D3. These rats with isolated hypophos-
cytosolic proteinsphatemia had marked decreases in PTH mRNA levels
and serum PTH. To demonstrate the effect of phosphate Moallem and colleagues utilized an in vitro degrada-
on the PT in vitro, it was imperative to maintain tissue tion assay to study the effects of hypocalcemic and hypo-
architecture [30–32]. There was an effect in whole glands phosphatemic parathyroid proteins of PTH mRNA sta-
or tissue slices but not in isolated cells. We are studying bility [24]. In this assay control rats’ PT cytosolic proteins
the mechanisms whereby dietary phosphate and calcium led to the degradation of a radiolabeled PTH transcript
regulate PTH gene expression. at about 40–60 min. Hypocalcemic PT proteins degraded
the transcript only at 180 min, while hypophosphatemic
PT proteins degraded the transcript already at 5 min (Fig.
PROTEIN-RNA INTERACTION AT THE
1A). Moreover, the rapid degradation of PTH mRNA by
PTH MRNA
hypophosphatemic proteins was totally dependent upon
Protein-RNA binding and its regulation by calcium an intact 39-untranslated region (UTR) and in particular
and phosphate the terminal 60 nt (Fig. 1B). Degradation with proteins
from other tissues in these rats was not regulated by cal-The clearest in vivo rat models for an effect of calcium
and phosphate on PTH gene expression are hypocal- cium or phosphate. Therefore, calcium and phosphate exert
their effect on the parathyroid cell to change the proper-cemia with a large increase in PTH mRNA levels and
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cell function, and role of Ca21 and other ions as extracellular (first)ties of cytosolic proteins that bind specifically to the PTH
messengers. Physiol Rev 71:371–411, 1991
mRNA 39-UTR and determine its stability (Fig. 2). 3. Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YW,
Riccardi D, Hebert SC: Calcium-ion-sensing cell-surface recep-
tors. N Engl J Med 333:234–240, 1995Identification of parathyroid cytosolic protein(s)
4. Demay MB, Kiernan MS, Deluca HF, Kronenberg HM: Se-binding the PTH mRNA 39-UTR
quences in the human parathyroid hormone gene that bind the
1,25-dihydroxyvitamin D3 receptor and mediate transcriptionalSela-Brown in our laboratory has now utilized affinity
repression in response to 1,25-dihydroxyvitamin D3. Proc Natlchromatography to isolate these RNA binding proteins.
Acad Sci USA 89:8097–8101, 1992
She recently presented preliminary information as to the 5. Farrow SM, Hawa NS, Karmali R, Hewison M, Walters JC,
O’Riordan JL: Binding of the receptor for 1,25-dihydroxyvitaminidentity of one of the PTH mRNA binding proteins (50
D3 to the 59-flanking region of the bovine parathyroid hormonekDa protein on SDS Page gel) and demonstrated its
gene. J Endocrinol 126:355–359, 1990
functionality (abstract; Bone 23:S15519, 1998). The pro- 6. Hawa NS, O’Riordan JL, Farrow SM: Binding of 1,25-dihydrox-
tein regulates PTH mRNA stability in degradation assays yvitamin D3 receptors to the 59-flanking region of the bovine para-
thyroid hormone gene. J Endocrinol 142:53–60, 1994in vitro. This preliminary observation should now be
7. Liu SM, Koszewski N, Lupez M, Malluche HH, Olivera A,
supplemented by the identification of the other pro- Russell J: Characterization of a response element in the 59-flank-
tein(s) (60 and 110 kDa) that form the protein complex ing region of the avian (chicken) parathyroid hormone gene that
mediates negative regulation of gene transcription by 1,25-dihy-on the PTH mRNA 39-UTR [33]. It might then be possi-
droxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocri-ble to understand how the different messages of changes nol 10:206–215, 1996
in serum calcium and phosphate are transduced to the 8. Silver J, Russell J, Sherwood LM: Regulation by vitamin D
metabolites of messenger ribonucleic acid for preproparathyroidparathyroid cytosol. These proteins then bind to the PTH
hormone in isolated bovine parathyroid cells. Proc Natl Acad ScimRNA 39-UTR and in particular the terminal 60 nt and USA 82:4270–4273, 1985
determine its stability. A stable transcript, for instance 9. Russell J, Silver J, Sherwood LM: The effects of calcium and
vitamin D metabolites on cytoplasmic mRNA coding for pre-pro-after hypocalcemia, would then be translated into the
parathyroid hormone in isolated parathyroid cells. Trans Assochormone and available for rapid secretion. An unstable Am Phys 97:296–303, 1984
transcript, such as after hypophosphatemia, would be 10. Cantley LK, Russell J, Lettieri D, Sherwood LM: 1,25-Dihy-
droxyvitamin D3 suppresses parathyroid hormone secretion fromrapidly degraded and less PTH translated and secreted.
bovine parathyroid cells in tissue culture. Endocrinology 117:2114–
2119, 1985
11. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, PopovtzerCONCLUSION MM: Regulation by vitamin D metabolites of parathyroid hormone
gene transcription in vivo in the rat. J Clin Invest 78:1296–1301,The PTH gene is regulated by a number of factors.
1986Calcitriol acts on the PTH gene to decrease its transcrip-
12. Russell J, Lettieri D, Sherwood LM: Suppression by 1,25
tion; and this action is used in the management of pa- (OH)2D3 of transcription of the pre-proparathyroid hormone gene.
Endocrinology 119:2864–2866, 1986tients with chronic renal failure. The main effect of cal-
13. Okazaki T, Igarashi T, Kronenberg HM: 59-flanking region ofcium on PTH gene expression in vivo is for hypocalcemia
the parathyroid hormone gene mediates negative regulation by
to increase PTH mRNA levels and this is post-transcrip- 1,25-(OH)2 vitamin D3. J Biol Chem 263:2203–2208, 1988
14. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J: Regulationtional. Phosphate also regulates PTH gene expression
of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-in vivo and this effect appears to be independent of
dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest
phosphate’s effects on serum calcium and 1,25(OH)2D3. 86:1968–1975, 1990
15. Patel SR, Ke HQ, Vanholder R, Koenig R, Hsu CH: InhibitionThe effect of phosphate is post-transcriptional. The ef-
of calcitriol receptor binding to vitamin D response elements byfect of both calcium and phosphate on PTH gene expres-
uremic toxin. J Clin Invest 96:50–59, 1995
sion is mediated by PT cytosolic proteins that bind to 16. Wheeler DG, Horsford J, Michalak M, White JH, Hendy GN:
the PTH mRNA 39-UTR and determine PTH mRNA Calreticulin inhibits vitamin D3 signal transduction. Nucleic Acids
Res 23:3268–3274, 1995stability.
17. Sela-Brown A, Russell J, Koszewski NJ, Michalak M, Naveh-
Many T, Silver J: Calreticulin inhibits vitamin D’s action on the
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